New biomarker for prognosis and treatment of patients with melanoma

The present invention relates to a method and composition for treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant. More particularly, inventors have shown that high expression of PTX3 correlates with melanoma invasiveness and with a poorer survival rate in metastatic melanoma patients. PTX3 knockdown inhibited melanoma cell migration, invasion, lung metastasis, and NFκB signaling pathway. An addition of melanoma-derived or recombinant PTX3, or overexpression of PTX3 enhanced motility of low migratory cells. Finally, they found that TLR4 and MYD88 knockdown or targeting inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4/NFkB-dependent pathway. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by quantifying the expression level of PTX3 in a biological sample and to a method of treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by using the inhibitors of PTX3.

Keywords: ELISA, RT-PCR, Immunoassay, Transcriptomics, Treatment Response, Prognosis in Melanoma, Cancer
Patent Application number: EP19 305 555.5
Inventors:
Mélanie TICHET Marcel DECKERT Moeez RATHORE Sophie TARTARE-DECKERT
Publications:
Oncogene. 2019 Jul;38(30):5873-5889. doi: 10.1038/s41388-019-0848-9. Epub 2019 Jun 28.

Reference:

BIO19137-D1

Business Developper
contact
Inserm Transfert
Inserm Transfert
Business Developer
Patent filling date: 2019-04-30

You might also be interested in